

**GLYCAL BASED DIVERSITY ORIENTED APPROACH TO THE
SYNTHESIS OF (–)-CONDURAMINE F-4, (–)-CONDURAMINE B-2,
ent-CONDURAMINE F-2, (+)-ANISOMYCIN, AMINOCYCLITOLS
AND IMINOCYCLITOLS**

VIMAL KANT HARIT



**DEPARTMENT OF CHEMISTRY
INDIAN INSTITUTE OF TECHNOLOGY DELHI
JUNE 2019**

© Indian Institute of Technology Delhi (IITD), New Delhi, 2019

**GLYCAL BASED DIVERSITY ORIENTED APPROACH TO THE
SYNTHESIS OF (–)-CONDURAMINE F-4, (–)-CONDURAMINE B-2,
ent-CONDURAMINE F-2, (+)-ANISOMYCIN, AMINOCYCLITOLS
AND IMINOCYCLITOLS**

by

**VIMAL KANT HARIT
DEPARTMENT OF CHEMISTRY**

submitted

*in fulfillment of the requirements of the degree of DOCTOR OF PHILOSOPHY
to the*



INDIAN INSTITUTE OF TECHNOLOGY DELHI

JUNE 2019

This thesis is dedicated to my beloved parents

(Late) Mr. Keshraj Singh and Mrs. Shashi Kanta

CERTIFICATE

This is to certify that the thesis entitled “**Glycal Based Diversity Oriented Approach to the Synthesis of (–)-Conduramine F-4, (–)-Conduramine B-2, ent-Conduramine F-2, (+)-Anisomycin, Aminocyclitols and Iminocyclitols**”, being submitted by **Mr. VIMAL KANT HARIT** to Indian Institute of Technology Delhi, for the award of the degree of **DOCTOR OF PHILOSOPHY**, is a record of bonafide research work carried out by him. Mr. VIMAL KANT HARIT has worked under my supervision and guidance and has fulfilled all the requirements for the submission of a Ph.D. thesis, which to my knowledge has reached the requisite standard and is worthy of consideration for the award of Ph.D. degree.

The work embodied in this thesis has not been submitted, in part or full, to other University or Institute for the award of any degree or diploma.

Prof. N. G. Ramesh
Supervisor
Department of Chemistry
Indian Institute of Technology
Delhi
Hauz Khas, New Delhi – 110016
India.

ACKNOWLEDGEMENTS

*I would like to express my sincere gratitude to my advisor and teacher **Prof. N. G. Ramesh**, who provided me the opportunity to pursue my PhD research in his laboratory. I am very grateful for his logistic support, continuous guidance, advice, effort and invertible suggestion throughout my research. Under his watchful eyes, he gave me the freedom to do whatever I wanted, at the same time continuing to contribute valuable feedback, advice, and encouragement. I would like to mention one of his saying “TRY ONE MORE TIME” helped me so many times, because whenever I stuck somewhere and started losing my interest, this quote only reinvigorated me to overcome that hurdle. His guidance helped during all my research as well as during writing of this thesis. I would also like to thank him for arranging all modern facilities and chemicals available, whenever it needed.*

*I would like to acknowledge **Prof. Ashok K. Ganguly**, head of the department for providing basic facilities for my research.*

*I would like to thank **Prof. Nalin Pant** for his valuable guidance and interest in my research. I am also grateful to **Prof. Jai D. Singh**, **Prof. B. Jayaram** and **Prof. Shivajirao L. Gholap**, and to my thesis committee members **Prof. V. Haridas** and **Prof. Veena Kaul** for their insightful comments and encouragement.*

I would like to thank DST INSPIRE for funding my doctoral work at IIT Delhi through JRF/SRF.

I thank to all my lab seniors late Dr. Vipin Kumar, Dr. M. Ganesan and Dr. P. Nagaraj for their pioneer work in setting platform for new objectives of research.

I would like to thank my fellow labmates Dr. Sathishkannan G., Dr. Rahul Vilas Salunke, Dr. Venkatesan S., Mr. Umesh Mishra, Mr. Abhishek Kulshrestha and Mr. Amit Kumar for their cooperation and for making joyful environment.

I would like to thank so many friends outside the lab, for all the great times that we have shared during past years, Dr. Dushyant Garg, Dr. Vinay Kumar, Dr. Jatinder Singh, Dr. Dharendra Yadav, Dr. Maninder Singh, Dr. Vineet Soni and Dr. Jassi Saggranwala.

I would like to thank IIT Delhi for providing institute facilities. I am thankful to Mr. Keshav, Mr. Alok from the NMR lab, Mr. Virender from the glass blowing section and Mr. Sharma from the instrumentation lab for facilitating my work. I also thank all technical staff of the department for their help.

*Last but not the least, I deeply thank my family: my parents late **Mr. Keshraj Singh** and **Mrs. Shashi Kanta**, for supporting me throughout my life and their graceful sacrifices to nurture our family. I would like to thank my wonderful family members for their love, moral support and appreciation.*

*Finally, I would like to give special thanks with love to my wife **Dr. Anju Rani** and my beloved daughter **Navanya**. I would like to thank my wife for her continued and unfailing love, support and understanding during my pursuit of Ph.D. degree that made the completion of thesis possible.*

(Vimal Kant Harit)

ABSTRACT

The thesis titled “**Glycal Based Diversity Oriented Approach to the Synthesis of (–)-Conduramine F-4, (–)-Conduramine B-2, ent-Conduramine F-2, (+)-Anisomycin, Aminocyclitols and Iminocyclitols**” presents the work carried out on the synthesis of all titled molecules starting from tri-*O*-benzyl-D-glucal. Enzyme inhibition studies against five commercially available glycosidases were also carried out.

Chapter I describes 'reagent-based diversity' strategy on a tri-*O*-benzyl-D-glucal derived 'common precursor' for the synthesis of three distinct target molecules of pharmacological relevance. In this chapter, for the first time, application of McMurry coupling for the construction of the six-membered carbocyclic aminocyclitols has been demonstrated. The first carbohydrate based approach towards the total synthesis of (–)-conduramine F-4 is reported. The chapter also describes the synthesis of amino-azepanes using double nucleophilic substitution which provided access to a collection of a few *N*-substituted azepane derivatives.

Chapter II describes a common strategy towards the synthesis of three structurally distinct target molecules, namely 1,4-Dideoxy-1,4-imino-L-xylitol (L-DIX), deacetyl (+)-anisomycin and amino-substituted piperidine iminosugars of biological and medicinal significance. The synthesis of common intermediate pyrrolidine was achieved through a novel concomitant ring closure upon oxidative cleavage of a vicinal diol derived in a few steps from tri-*O*-benzyl-D-glucal.

Chapter III describes a ring closing metathetical (RCM) approach for the synthesis of six membered and five membered aminocyclitols. This chapter also reports a novel glycosylation reaction on a tri-*O*-benzyl-D-glucal derived 2-iodo-2-deoxy-1-(*p*-

toluenesulfonamido) derivative for the synthesis of methyl-2-deoxy-2-(*p*-toluenesulfonamido)- β -D-glucoside, which was taken forward to synthesize a common formyl-olefin intermediate. Through RCM of appropriate substrates, synthesized from the common intermediate, three structurally different types of molecules were obtained.

सार

थीसिस का शीर्षक "ग्लाइकॉल आधारित विविधता ओरिएंटेड एप्रोच टू द सिन्थेसिस ऑफ़ (-)-कॉन्ड्यूरामाइन F-4, (-)-कॉन्ड्यूरामाइन B-2, कॉन्ड्यूरामाइन F-2, (+)-एनिसोमाइसिन, अमीनोसायक्लिटोल्स और इमिनोसायक्लिटोल्स है। त्रि-ओ-बेंजाइल-डी-ग्लुकल से शुरू होने वाले सभी शीर्षक वाले अणुओं के संश्लेषण पर किए गए कार्य को प्रस्तुत करता है। पांच व्यावसायिक रूप से उपलब्ध ग्लाइकोसिडेसिस के खिलाफ एंजाइम निषेध अध्ययन भी किए गए।

अध्याय I, औषधीय प्रासंगिकता के तीन अलग-अलग लक्ष्य अणुओं के संश्लेषण के लिए त्रि-ओ- बेंजाइल-डी-ग्लुकल व्युत्पन्न 'सामान्य अग्रदूत' पर 'अभिकर्मक-आधारित विविधता' रणनीति का वर्णन करता है। इस अध्याय में, पहली बार, छह-सदस्यीय कार्बोसाइक्लिक एमिनोसाइक्लिटोल्स के निर्माण के लिए मैकमरी कपलिंग के उपयोग का प्रदर्शन किया गया है। (-)-कॉन्ड्यूरामाइन F-4 के कुल संश्लेषण के प्रति पहला कार्बोहाइड्रेट आधारित दृष्टिकोण बताया गया है। अध्याय में डबल न्यूक्लियोफिलिक प्रतिस्थापन का उपयोग करते हुए अमीनो-एजेपेंस के संश्लेषण का भी वर्णन किया गया है।

अध्याय II, में तीन संरचनात्मक रूप से अलग लक्ष्य अणुओं के संश्लेषण की दिशा में एक सामान्य रणनीति का वर्णन किया गया है, जैविक और औषधीय महत्व के अणुओं, क्रमशः 1,4-डिऑक्सी-1,4-इमिनो-एल-ज़ाइलिटोल (एल-डीक्स), डीएसेटाइल (+)-एनिसोमाइसीन और एमिनो-प्रतिस्थापित पिपेरिडीन इमिनोसुगर शामिल हैं। त्रि-ओ-बेंजाइल-डी-ग्लुकल से कुछ ही चरणों में व्युत्पन्न एक विसीनल डायोल के ऑक्सीडेटिव क्लैवेज पर एक सहचारी रिंग क्लोजर के माध्यम से सामान्य मध्यवर्ती पाइरोलिडीन के संश्लेषण को प्राप्त किया गया।

अध्याय III, में छह सदस्यीय और पांच सदस्यीय अमीनोसायक्लिटोल्स के संश्लेषण के लिए एक रिंग क्लोजिंग मेटाथैटिकल (RCM) दृष्टिकोण का वर्णन किया गया है। इस अध्याय में त्रि-ओ-बेंजाइल-डी-ग्लुकल व्युत्पन्न 2-आयोडो-2-डीऑक्सी-1-(पी-टोलुइनसल्फोनोमीडो)-D-ग्लूकोज पर एक नई ग्लाइकोसिलेशन प्रतिक्रिया का वर्णन किया गया है, फिर जिसे एक सामान्य फॉर्मिल-ओलेफिन मध्यवर्ती

को संश्लेषित करने के लिए किया गया। सामान्य मध्यवर्ती से संश्लेषित, उपयुक्त सब्सट्रेट्स के आरसीएम के माध्यम से, तीन संरचनात्मक रूप से विभिन्न प्रकार के अणु प्राप्त किए गए।

TABLE OF CONTENTS

	PAGE
CERTIFICATE	I
ACKNOWLEDGEMENTS	II
ABSTRACT	IV
HINDI ABSTRACT	VI
TABLE OF CONTENTS	VIII
LIST OF FIGURES	X
LIST OF TABLES	XVI
GENERAL EXPERIMENTAL CONSIDERATIONS	XVII
COMMON ABBREVIATIONS	XIX
CHAPTER	
I A Chiron Approach to Diversity Oriented Synthesis of Aminocyclitols, (–)-Conduramine F-4 and Polyhydroxyaminoazepanes from a Common Precursor.	
1.1 Introduction	1
1.2 Objective	26
1.3 Results and discussion	28
1.4 Conclusions	40
1.5 Experimental Section	41
1.6 References	82
1.7 Copies of NMR spectra of selected compounds	90

CHAPTER

II A Common Strategy towards the Synthesis of 1,4-Dideoxy-1,4-imino-L-xylitol (L-DIX), Deacetyl (+)-anisomycin and Amino-substituted Piperidine Iminosugars.

2.1 Introduction	141
2.2 Objective	167
2.3 Results and discussion	169
2.4 Conclusions	177
2.5 Experimental Section	178
2.6 References	209
2.7 Copies of NMR spectra of selected compounds	215

CHAPTER

III Ring Closing Metathetical (RCM) Approach to the Synthesis of (–)-Conduramine B-2, *ent*-Conduramine F-2, Aminocyclopentinitol and Polyhydroxyazepane.

3.1 Introduction	249
3.2 Objective	264
3.3 Results and discussion	266
3.4 Conclusions	276
3.5 Experimental Section	277
3.6 References	305
3.7 Copies of NMR spectra of selected compounds	309

LIST OF PUBLICATIONS	346
-----------------------------	------------

A BRIEF CV OF THE AUTHOR	347
---------------------------------	------------

LIST OF FIGURES

CHAPTER I		PAGE
Figure 1.1	Structures of inositols	1
Figure 1.2	Selected examples of aminocyclitol antibiotics and amaryllidaceae alkaloids	2
Figure 1.3	Structures of various conduritols	12
Figure 1.4	Structures of conduramines	13
Figure 1.5	Structures of natural products that are derived from conduramines	14
Figure 1.6	Examples of seven-membered iminocyclitols	19
Figure 1.7	Probable mechanistic explanation for selectivity in McMurry coupling of compound 184	33
Figure 1.8	^1H -NMR spectrum of compound 182	90
Figure 1.9	^{13}C -NMR spectrum of compound 182	90
Figure 1.10	^1H -NMR spectrum of compound 188	91
Figure 1.11	^{13}C -NMR spectrum of compound 188	91
Figure 1.12	^1H -NMR spectrum of compound 189	92
Figure 1.13	^{13}C -NMR spectrum of compound 189	92
Figure 1.14	^1H -NMR spectrum of compound 191	93
Figure 1.15	^{13}C -NMR spectrum of compound 191	93
Figure 1.16	^1H -NMR spectrum of compound 190	94
Figure 1.17	^1H -NMR spectrum of compound 190 (expanded spectrum)	94
Figure 1.18	^{13}C -NMR spectrum of compound 190	95
Figure 1.19	^1H -NMR spectrum of compound 183	96
Figure 1.20	^{13}C -NMR spectrum of compound 183	96
Figure 1.21	^1H -NMR spectrum of compound 184	97
Figure 1.22	^1H -NMR spectrum of compound 193	98
Figure 1.23	^{13}C -NMR spectrum of compound 193	98
Figure 1.24	^1H -NMR spectrum of compound 193	99
Figure 1.25	^{13}C -NMR spectrum of compound 193	99
Figure 1.26	^1H -NMR spectrum of compound 194	100
Figure 1.27	^{13}C -NMR spectrum of compound 194	100
Figure 1.28	^1H -NMR spectrum of compound 194	101
Figure 1.29	^{13}C -NMR spectrum of compound 194	101
Figure 1.30	^1H -NMR spectrum of compound 195	102
Figure 1.31	^1H -NMR spectrum of compound 195 (expanded spectrum)	102
Figure 1.32	^{13}C -NMR spectrum of compound 195	103
Figure 1.33	^1H - ^1H COSY spectrum of compound 195	103
Figure 1.34	^1H - ^1H COSY spectrum of compound 195 (expanded spectrum)	104
Figure 1.35	^1H - ^{13}C HSQC spectrum of compound 195	104
Figure 1.36	^1H - ^{13}C HSQC spectrum of compound 195 (expanded spectrum)	105
Figure 1.37	^1H - ^1H NOESY spectrum of compound 195	105
Figure 1.38	^1H - ^1H NOESY spectrum of compound 195 (expanded spectrum)	106
Figure 1.39	^1H -NMR spectrum of compound 196	107
Figure 1.40	^{13}C -NMR spectrum of compound 196	107

Figure 1.41	¹ H-NMR spectrum of compound 197	108
Figure 1.42	¹³ C-NMR spectrum of compound 197	108
Figure 1.43	¹ H-NMR spectrum of compound 198	109
Figure 1.44	¹ H-NMR spectrum of compound 198	109
Figure 1.45	¹³ C-NMR spectrum of compound 198	110
Figure 1.46	¹ H-NMR spectrum of compound 199	111
Figure 1.47	¹³ C-NMR spectrum of compound 199	111
Figure 1.48	¹ H-NMR spectrum of compound 200	112
Figure 1.49	¹³ C-NMR spectrum of compound 200	112
Figure 1.50	¹ H-NMR spectrum of compound 201	113
Figure 1.51	¹³ C-NMR spectrum of compound 201	113
Figure 1.52	¹ H-NMR spectrum of compound 186	114
Figure 1.53	¹³ C-NMR spectrum of compound 186	114
Figure 1.54	¹ H-NMR spectrum of compound 202	115
Figure 1.55	¹³ C-NMR spectrum of compound 202	115
Figure 1.56	¹ H-NMR spectrum of compound 203	116
Figure 1.57	¹³ C-NMR spectrum of compound 203	116
Figure 1.58	¹ H-NMR spectrum of compound 206	117
Figure 1.59	¹³ C-NMR spectrum of compound 206	117
Figure 1.60	Variable Temperature ¹ H-NMR spectrum of compound 206 in DMSO at 25 °C	118
Figure 1.61	Variable Temperature ¹ H-NMR spectrum of compound 206 in DMSO at 99 °C	118
Figure 1.62	¹ H-NMR spectrum of compound 98 (–)-conduramine F-4	119
Figure 1.63	¹ H-NMR spectrum of compound 98 (–)-conduramine F-4	119
Figure 1.64	¹³ C-NMR spectrum of compound 98 (–)-conduramine F-4	120
Figure 1.65	¹ H-NMR spectrum of compound 204	121
Figure 1.66	¹³ C-NMR spectrum of compound 204	121
Figure 1.67	¹ H-NMR spectrum of compound 205	122
Figure 1.68	¹³ C-NMR spectrum of compound 205	122
Figure 1.69	¹ H-NMR spectrum of compound 205	123
Figure 1.70	¹³ C-NMR spectrum of compound 205	123
Figure 1.71	¹ H-NMR spectrum of compound 207	124
Figure 1.72	¹³ C-NMR spectrum of compound 207	124
Figure 1.73	¹ H-NMR spectrum of compound 208	125
Figure 1.74	¹³ C-NMR spectrum of compound 208	125
Figure 1.75	¹ H-NMR spectrum of compound 208	126
Figure 1.76	¹³ C-NMR spectrum of compound 208	126
Figure 1.77	¹ H-NMR spectrum of compound 209	127
Figure 1.78	¹³ C-NMR spectrum of compound 209	127
Figure 1.79	¹ H-NMR spectrum of compound 210	128
Figure 1.80	¹³ C-NMR spectrum of compound 210	128
Figure 1.81	¹ H-NMR spectrum of compound 211	129
Figure 1.82	¹³ C-NMR spectrum of compound 211	129
Figure 1.83	¹ H-NMR spectrum of compound 212	130
Figure 1.84	¹³ C-NMR spectrum of compound 212	130
Figure 1.85	¹ H-NMR spectrum of compound 213	131
Figure 1.86	¹ H-NMR spectrum of compound 213 (expanded spectrum)	131

Figure 1.87	¹³ C-NMR spectrum of compound 213	132
Figure 1.88	¹ H-NMR spectrum of compound 214	133
Figure 1.89	¹³ C-NMR spectrum of compound 214	133
Figure 1.90	¹ H-NMR spectrum of compound 215	134
Figure 1.91	¹³ C-NMR spectrum of compound 215	134
Figure 1.92	¹ H-NMR spectrum of compound 216	135
Figure 1.93	¹³ C-NMR spectrum of compound 216	135
Figure 1.94	¹ H-NMR spectrum of compound 217	136
Figure 1.95	¹³ C-NMR spectrum of compound 217	136
Figure 1.96	¹ H-NMR spectrum of compound 218	137
Figure 1.97	¹³ C-NMR spectrum of compound 218	137
Figure 1.98	¹ H-NMR spectrum of compound 219	138
Figure 1.99	¹³ C-NMR spectrum of compound 219	138
Figure 1.100	ORTEP plot of the crystal structure of 194	139
CHAPTER II		
Figure 2.1	Structures of DAB, LAB, D-DIX, L-DIX	141
Figure 2.2	Structures of (–)-anisomycin, deacetyl (–)-anisomycin and their enantiomers	155
Figure 2.3	Structures of piperidine iminocyclitols and marketed drugs (miglitol and zavesca)	164
Figure 2.4	¹ H-NMR spectrum of compound 144	215
Figure 2.5	¹³ C-NMR spectrum of compound 144	215
Figure 2.6	¹ H-NMR spectrum of compound 147	216
Figure 2.7	¹³ C-NMR spectrum of compound 147	216
Figure 2.8	¹ H-NMR spectrum of compound 4	217
Figure 2.9	¹ H-NMR spectrum of compound 4 (expanded spectrum)	217
Figure 2.10	¹³ C-NMR spectrum of compound 4	218
Figure 2.11	¹ H-NMR spectrum of compound 150	219
Figure 2.12	¹³ C-NMR spectrum of compound 150	219
Figure 2.13	¹ H-NMR spectrum of compound 151	220
Figure 2.14	¹ H-NMR spectrum of compound 151 (expanded spectrum)	220
Figure 2.15	¹³ C-NMR spectrum of compound 151	221
Figure 2.16	¹ H-NMR spectrum of compound 152	222
Figure 2.17	¹³ C-NMR spectrum of compound 152	222
Figure 2.18	¹ H-NMR spectrum of compound 153	223
Figure 2.19	¹³ C-NMR spectrum of compound 153	223
Figure 2.20	¹ H-NMR spectrum of compound 154	224
Figure 2.21	¹³ C-NMR spectrum of compound 154	224
Figure 2.22	¹ H-NMR spectrum of compound 155	225
Figure 2.23	¹³ C-NMR spectrum of compound 155	225
Figure 2.24	¹ H-NMR spectrum of compound 156	226
Figure 2.25	¹³ C-NMR spectrum of compound 156	226
Figure 2.26	¹ H-NMR spectrum of compound 157	227
Figure 2.27	¹³ C-NMR spectrum of compound 157	227
Figure 2.28	¹ H-NMR spectrum of compound (+)- 81	228
Figure 2.29	¹ H-NMR spectrum of compound (+)- 81	228
Figure 2.30	¹³ C-NMR spectrum of compound (+)- 81	229

Figure 2.31	¹ H-NMR spectrum of compound 158	230
Figure 2.32	¹³ C-NMR spectrum of compound 158	230
Figure 2.33	¹ H-NMR spectrum of compound 145	231
Figure 2.34	¹³ C-NMR spectrum of compound 145	231
Figure 2.35	¹ H-NMR spectrum of compound 159	232
Figure 2.36	¹³ C-NMR spectrum of compound 159	232
Figure 2.37	¹ H-NMR spectrum of compound 160	233
Figure 2.38	¹³ C-NMR spectrum of compound 160	233
Figure 2.39	¹ H-NMR spectrum of compound 161	234
Figure 2.40	¹³ C-NMR spectrum of compound 161	234
Figure 2.41	¹ H-NMR spectrum of compound 162	235
Figure 2.42	¹³ C-NMR spectrum of compound 162	235
Figure 2.43	¹ H-NMR spectrum of compound 163	236
Figure 2.44	¹³ C-NMR spectrum of compound 163	236
Figure 2.45	¹ H-NMR spectrum of compound 164	237
Figure 2.46	¹³ C-NMR spectrum of compound 164	237
Figure 2.47	¹ H-NMR spectrum of compound 165	238
Figure 2.48	¹³ C-NMR spectrum of compound 165	238
Figure 2.49	¹ H-NMR spectrum of compound 166	239
Figure 2.50	¹³ C-NMR spectrum of compound 166	239
Figure 2.51	¹ H-NMR spectrum of compound 167	240
Figure 2.52	¹ H-NMR spectrum of compound 167 (expanded spectrum)	240
Figure 2.53	¹³ C-NMR spectrum of compound 167	241
Figure 2.54	¹ H-NMR spectrum of compound 168	242
Figure 2.55	¹ H-NMR spectrum of compound 168 (expanded spectrum)	242
Figure 2.56	¹³ C-NMR spectrum of compound 168	243
Figure 2.57	¹ H-NMR spectrum of compound 169	244
Figure 2.58	¹³ C-NMR spectrum of compound 169	244
Figure 2.59	¹ H-NMR spectrum of compound 170	245
Figure 2.60	¹³ C-NMR spectrum of compound 170	245
Figure 2.61	¹ H-NMR spectrum of compound 171	246
Figure 2.62	¹³ C-NMR spectrum of compound 171	246
Figure 2.63	¹ H-NMR spectrum of compound 172	247
Figure 2.64	¹³ C-NMR spectrum of compound 172	247
Figure 2.65	¹ H-NMR spectrum of compound 173	248
Figure 2.66	¹³ C-NMR spectrum of compound 173	248
CHAPTER III		
Figure 3.1	Structures of conduritols and their corresponding X-2 or X-3 conduramines	250
Figure 3.2	Structures of aminocyclopentitol and related biologically active important compounds	253
Figure 3.3	Examples of pyrrolidine, piperidine and azepane iminosugars	261
Figure 3.4	NOE correlations for compounds 117 and 118 .	269
Figure 3.5	¹ H-NMR spectrum of compound 105	309
Figure 3.6	¹³ C-NMR spectrum of compound 105	309
Figure 3.7	¹ H-NMR spectrum of compound 106	310
Figure 3.8	¹³ C-NMR spectrum of compound 106	310

Figure 3.9	^1H -NMR spectrum of compound 112	311
Figure 3.10	^{13}C -NMR spectrum of compound 112	311
Figure 3.11	^1H -NMR spectrum of compound 107	312
Figure 3.12	^{13}C -NMR spectrum of compound 107	312
Figure 3.13	^1H -NMR spectrum of compound 108	313
Figure 3.14	^{13}C -NMR spectrum of compound 108	313
Figure 3.15	^1H -NMR spectrum of compound 113	314
Figure 3.16	^{13}C -NMR spectrum of compound 113	314
Figure 3.17	^1H -NMR spectrum of compound 114	315
Figure 3.18	^{13}C -NMR spectrum of compound 114	315
Figure 3.19	^1H -NMR spectrum of compound 115	316
Figure 3.20	^{13}C -NMR spectrum of compound 115	316
Figure 3.21	^1H -NMR spectrum of compound 116	317
Figure 3.22	^{13}C -NMR spectrum of compound 116	317
Figure 3.23	^1H -NMR spectrum of compound 117	318
Figure 3.24	^{13}C -NMR spectrum of compound 117	318
Figure 3.25	^1H - ^{13}C HSQC spectrum of compound 117	319
Figure 3.26	^1H - ^1H COSY spectrum of compound 117	319
Figure 3.27	^1H - ^1H NOESY spectrum of compound 117	320
Figure 3.28	^1H -NMR spectrum of compound 118	321
Figure 3.29	^{13}C -NMR spectrum of compound 118	321
Figure 3.30	^1H - ^{13}C HSQC spectrum of compound 118	322
Figure 3.31	^1H - ^1H COSY spectrum of compound 118	322
Figure 3.32	^1H - ^1H COSY spectrum of compound 118 (expanded spectrum)	323
Figure 3.33	^1H - ^1H NOESY spectrum of compound 118	323
Figure 3.34	^1H - ^1H NOESY spectrum of compound 118 (expanded spectrum)	324
Figure 3.35	^1H - ^1H NOESY spectrum of compound 118 (extra expanded spectrum)	324
Figure 3.36	^1H -NMR spectrum of compound 119	325
Figure 3.37	^{13}C -NMR spectrum of compound 119	325
Figure 3.38	^1H -NMR spectrum of compound 120	326
Figure 3.39	^{13}C -NMR spectrum of compound 120	326
Figure 3.40	^1H -NMR spectrum of compound 121	327
Figure 3.41	^{13}C -NMR spectrum of compound 121	327
Figure 3.42	^1H -NMR spectrum of compound 122	328
Figure 3.43	^{13}C -NMR spectrum of compound 122	328
Figure 3.44	^1H -NMR spectrum of compound 123	329
Figure 3.45	^{13}C -NMR spectrum of compound 123	329
Figure 3.46	^1H -NMR spectrum of compound 111	330
Figure 3.47	^{13}C -NMR spectrum of compound 111	330
Figure 3.48	^1H -NMR spectrum of compound 124	331
Figure 3.49	^1H -NMR spectrum of compound 124 (expanded spectrum)	331
Figure 3.50	^{13}C -NMR spectrum of compound 124	332
Figure 3.51	^1H -NMR spectrum of compound 38	333
Figure 3.52	^1H -NMR spectrum of compound 38	333
Figure 3.53	^{13}C -NMR spectrum of compound 38	334

Figure 3.54	¹ H-NMR spectrum of compound 125	335
Figure 3.55	¹³ C-NMR spectrum of compound 125	335
Figure 3.56	¹ H-NMR spectrum of compound 126	336
Figure 3.57	¹³ C-NMR spectrum of compound 126	336
Figure 3.58	¹ H-NMR spectrum of compound 127	337
Figure 3.59	¹ H-NMR spectrum of compound 127 (expanded spectrum)	337
Figure 3.60	¹³ C-NMR spectrum of compound 127	338
Figure 3.61	¹ H-NMR spectrum of compound 109	339
Figure 3.62	¹³ C-NMR spectrum of compound 109	349
Figure 3.63	¹ H-NMR spectrum of compound 128	340
Figure 3.64	¹ H-NMR spectrum of compound 128 (expanded spectrum)	340
Figure 3.65	¹³ C-NMR spectrum of compound 128	341
Figure 3.66	¹ H-NMR spectrum of compound 129	342
Figure 3.67	¹ H-NMR spectrum of compound 129 (expanded spectrum)	342
Figure 3.68	¹³ C-NMR spectrum of compound 129	343
Figure 3.69	¹ H-NMR spectrum of compound 92	344
Figure 3.70	¹ H-NMR spectrum of compound 92 (expanded spectrum)	344
Figure 3.71	¹³ C-NMR spectrum of compound 92	345

LIST OF TABLES

CHAPTER I		PAGE
Table 1.1	Reaction optimization conditions for McMurry coupling	31
Table 1.2	Glycosidase inhibition studies	37
CHAPTER II		
Table 2.1	Glycosidase inhibition studies	175
CHAPTER III		
Table 3.1	Glycosidase inhibition studies	274

GENERAL EXPERIMENTAL CONSIDERATIONS

All solvents employed were purified by standard procedures. Anhydrous solvents were dried over sodium wire (THF, diethyl ether, benzene) or molecular sieves (CH_2Cl_2 , CHCl_3 , DMF).

Nitrogen or Argon gas used for creating inert atmosphere was freed from oxygen prior to entry into reaction vessel.

Commercially sourced TLC plates were used, and the spots were visualized by exposure to iodine, or by dipping in KMnO_4 solution. Column chromatography was carried out on silica gel (230–400 mesh) using mixtures of hexane and ethyl acetate as eluent unless otherwise mentioned.

Optical rotations were recorded on an Autopol V (Rudolph Research Flanders, NJ) instrument. All the rotations were measured at 589 nm (sodium D' line).

All melting points reported in this thesis are uncorrected and were taken on an electric melting point apparatus (Ambassador, India).

Freeze-drying of samples was done on a Freezone 2.5 (Labconco, USA) lyophilizer.

Inhibition studies were carried out on Biotek Synergy 2 microplate reader.

IR spectra were taken within the range $4000\text{--}600\text{ cm}^{-1}$ as KBr pellets on a Nicolet (Madison, USA) FT-IR spectrophotometer (Model Protégé 460).

^1H -NMR spectra were recorded on a 300 MHz or 400 MHz Bruker Spectrospin DPX FT-NMR instruments. The solvents employed were CDCl_3 , D_2O or $\text{DMSO-}d_6$ with Me_4Si as the internal standard. The multiplicities are denoted as s-singlet, brs-broad singlet, d-doublet, brm-broad multiplet, t-triplet, q-quartet, dt-doublet triplet and m-multiplet. ^{13}C -NMR spectra were recorded at 75 MHz or at 100 MHz instrument. The chemical shifts are reported in δ values (parts per million, ppm) relative to the internal standard Me_4Si .

High-resolution mass spectra were recorded with a Q-TOF Bruker instrument, using electrospray ionization (ESI) as the ionization method.

COMMON ABBREVIATIONS

aq	:	Aqueous
Bn	:	Benzyl
BnBr	:	Benzyl bromide
BnOH	:	Benzyl alcohol
Boc	:	Tertiary-butoxycarbonyl
n-BuLi	:	<i>n</i> -Butyllithium
BzCl	:	Benzoyl chloride
<i>c</i>	:	Concentration
Cat	:	Catalyst
Cbz	:	Carbobenzyloxy
CbzCl	:	Carboxybenzyl chloride
Conc.	:	Concentrated
COSY	:	Correlation Spectroscopy
mCPBA	:	Meta chloro perbenzoic acid
CSA	:	Camphor sulphonic acid
CSO	:	Carbonyl sulfide
DBU	:	1,8-Diazabicyclo[5.4.0]undec-7-ene
DCC	:	<i>N, N'</i> -dicyclohexylcarbodiimide
DCN	:	1,4-dicyanonaphthalene
de	:	Diastereomeric excess
DEAD	:	Diethyl azodicarboxylate
DIBAL-H	:	Diisobutylaluminium hydride
DIPEA	:	<i>N,N</i> -Diisopropylethylamine
DMAP	:	4-Dimethylaminopyridine
DME	:	Dimethoxyethane
DMF	:	<i>N, N'</i> -dimethylformamide
DMP	:	2,2-Dimethoxy propane
DMSO	:	Dimethylsulfoxide
<i>dr</i>	:	Diastereomeric ratio
ee	:	Enantiomeric excess

ent	:	Enantiomer
Et ₃ SiH	:	Triethylsilane
epi	:	Epimer
equiv	:	Equivalent
g	:	Gram
GalNAcase	:	<i>N</i> -acetyl- α -D-galactosaminidase
G _{M1}	:	Monosialotetrahexosylganglioside
h	:	Hour
HRMS	:	High Resolution Mass Spectrometry
HSQC	:	Heteronuclear Single Quantum Coherence
Hz	:	Hertz
IC ₅₀	:	Half maximal Inhibitory Concentration
Imd	:	Imidazole
IR	:	Infrared
K _i	:	Inhibition Constant
KHMDS	:	Potassium <i>bis</i> (trimethylsilyl)amide
LAH	:	Lithium aluminium hydride
LDA	:	Lithium diisopropyl amide
liq	:	Liquid
Martin sulfurane	:	Bis[α,α -bis(trifluoromethyl)benzyloxy]diphenylsulfur
Me	:	Methyl
MeCN	:	Acetonitrile
mg	:	Milligrams
MHz	:	Megahertz
min	:	Minute
mL	:	Milliliters
mM	:	Millimolar
mmol	:	Millimoles
μ M	:	Micromolar
MOMI	:	Methoxymethyl iodide
M.P.	:	Melting Point
Ms	:	Mesyl

MS	:	Molecular sieves
MsCl	:	Methanesulfonyl chloride
MW	:	Microwave
m/z	:	mass-to-charge ratio
NaH	:	Sodium hydride
NHC	:	<i>N</i> -Heterocyclic carbene
nM	:	Nanomolar
NMO	:	4-Methylmorpholine <i>N</i> -oxide
NMR	:	Nuclear magnetic resonance
Nu	:	Nucleophile
PDC	:	Pyridinium Dichromate
Pd/C	:	Palladium on activated carbon
Ph	:	Phenyl
PivCl	:	Pivaloyl chloride
ppm	:	Parts per million
PPTS	:	Pyridinium <i>p</i> -toluenesulfonate
ⁱ Pr	:	Isopropyl
Py	:	Pyridine
<i>R_f</i>	:	Retention factor
ref	:	Reference
rt	:	Room temperature
TBATB	:	Tetrabutylammonium tribromide
TFA	:	Trifluoroacetic acid
Ts	:	Para-toluenesulfonyl
)))	:	Sonication